Stephanie Michelsen
CEO
Jellatech
Jellatech produces bio-identical complex proteins, including native Type I collagen, using advanced cellular agriculture and synthetic biology. This process eliminates reliance on animal-derived sources, ensuring high-quality, consistent, and ethical protein supply for various industries. The resulting cultivated proteins offer scalable production with guaranteed quality for biomedical, pharmaceutical, and consumer applications.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional collagen production relies on animal sources, raising ethical concerns and the risk of disease transmission. Animal-derived collagen can also suffer from batch-to-batch variability and scalability limitations.
Solution
Jellatech uses cell culture to produce bio-identical, animal-free collagen. A one-time skin biopsy is used to initiate cell lines, creating a scalable and ethical solution. The company selects top-performing cells and optimizes environmental variables to maximize collagen production. Jellatech's proprietary methods purify the harvested collagen to >95%, resulting in native triple helix collagen type I with native hydroxyproline levels required for full functionality.
Target Audience
Jellatech serves the biopharma, food, cosmetics, research and development, biomedical and health, materials and processes industries.
Features
- Production of bio-identical human collagen via cell culture
- Animal-free process eliminates ethical concerns and disease transmission risks
- Scalable production to meet growing collagen demand
- Proprietary purification methods to achieve >95% purity
- Native triple helix collagen type I with native hydroxyproline levels